SCHAFFHAUSEN, SWITZERLAND / ACCESSWIRE / September 6, 2022 / Occlutech Holding AG (“Occlutech”), one of the world’s leading providers of minimally invasive devices for structural heart disease, has expanded its executive management team with the appointment of two new members. Jose de la Cortina was hired as Chief Commercial Officer (CCO) and Mathias Bouzereau as Vice President (VP) Global Business Development & Marketing.
The new members of Occlutech’s executive management team have extensive experience in their areas of expertise and responsibilities as follows:
Jose de la Cortina (CCO) was born in 1973 and holds a Science degree in Medical Biology from Université du Québec à Trois-Rivières, Canada, and a Business Degree in International Business from Concordia University in Montreal, Canada. Over the past 23 years, Jose has been instrumental in the tremendous success story of Baylis Medical, which was acquired this year by Boston Scientific for $1.75 billion. He has driven commercialization in the US, Japan, Europe and many other regions. At Occlutech, Jose will have full responsibility for development and commercial strategies while driving global sales, growth and profitability in over 85 markets.
Mathias Bouzereau (VP Business Development & Marketing) was born in 1971 and holds a Master of Business Administration from IMD Business School in Lausanne, Switzerland, a Master of Science in Computer Science from INSA Lyon, France, and the University of Nottingham, UK. Mathias has experience at Gemalto/Gemplus (now part of Thales) where he held several senior positions in Europe and Latin America, helping to transform a start-up into a €2 billion multinational. He also has 13 years of experience at Medtronic, where he held marketing positions in the field of congenital therapies and strategic marketing in the Structural Heart Division. At Occlutech, Mathias will lead Business Development & Marketing to build the product pipeline and execute global product strategies while driving growth to strengthen Occlutech as a global leader in specialty cardiac devices.
“I am pleased that we are expanding Occlutech’s executive management team with two new, highly qualified and motivated individuals with extensive experience and know-how that will contribute significantly to Occlutech’s continued growth trajectory,” said Sabine Bois, CEO of Occlutech.
As of September 1, 2022, Occlutech’s Executive Management Team will consist of 9 members. In addition to Sabine Bois (CEO) and the two new members mentioned above, they also include Thomas Okke Frahm (VP IT), Sakarias Lindell (VP People & Culture), Luis Martin-Parras (VP Supply Chain & Manufacturing), Oshri Budana ( VP Clinical & RA/Q), Frank Dallmann (VP R&D) and Lars Wadell (CFO).
For more information, please contact:
Occlutech is a leading specialty provider of minimally invasive structural heart implants dedicated to improving the quality of life for people living with heart disease. The vision is to become a leading global cardiac implant specialist, addressing congenital heart defects, stroke prevention and heart failure. The company has been developing, producing and selling occluders and interatrial shunt products since 2003. Occlutech has a broad and proven portfolio based on proprietary technology and over 200 patents with more than 150,000 products sold. The company markets and sells its products in around 85 countries. The company employs around 290 people and is a public limited company registered in Switzerland. For more information: www.occlutech.com.
Occlutech Announces New Executive Management Team Members – Appoints Chief Commercial Officer and Vice President Global Business Development & Marketing
SOURCE: Occlutech Holding AG
View source version on accesswire.com: